Portal de Periódicos da CAPES

INTERFERENCE OF MODERN ANTIBACTERIALS WITH BACILLUS CALMETTE-GUERIN VIABILITY

1999; Lippincott Williams & Wilkins; Volume: 162; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(05)68078-0

1527-3792

Christoph Durek, Sabine Rüsch–Gerdes, D. Jocham, Andreas Böhle,

Reproductive tract infections research

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 1999INTERFERENCE OF MODERN ANTIBACTERIALS WITH BACILLUS CALMETTE-GUERIN VIABILITY CHRISTOPH DUREK, SABINE RÜSCH-GERDES, DIETER JOCHAM, and ANDREAS BÖHLE CHRISTOPH DUREKCHRISTOPH DUREK More articles by this author , SABINE RÜSCH-GERDESSABINE RÜSCH-GERDES More articles by this author , DIETER JOCHAMDIETER JOCHAM More articles by this author , and ANDREAS BÖHLEANDREAS BÖHLE More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68078-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determine the effects of modern antibacterial chemotherapeutics on bacillus Calmette-Guerin (BCG) viability, particularly those of cycloserine, which has been recommended for treating BCG induced sepsis. Materials and Methods: The minimal inhibitory concentrations of 31 antibacterial drugs against Connaught BCG strain were determined in vitro by the radiometric BACTEC 460TB method. * Becton Dickinson Diagnostic Instruments, Sparks, Maryland. Minimal inhibitory concentrations were compared with the drug concentrations achievable in blood and urine to estimate systemic or intravesical susceptibility. Susceptibility testing of cycloserine was performed with Connaught, Tice and RIVM BCG strains, using the modified proportion method on Löwenstein-Jensen agar. Results: Connaught BCG was susceptible to quinolones in systemic infections but resistant to β-lactams, macrolides and some aminoglycosides. It was resistant to pyrazinamide but showed good susceptibility toward the other antituberculosis drugs tested. All 3 BCG strains analyzed were resistant to cycloserine. Most antibacterials may interfere with BCG in the bladder because of high urinary recovery. Conclusions: Antibacterial drug interference with BCG viability should be avoided during intravesical instillation therapy. In cases of severe complications quinolones rather than cycloserine may be given in addition to standard triple antituberculosis drug therapy or if one of these drugs is not tolerated. Our data may contribute toward enhancing the therapeutic safety and efficacy of intravesical BCG immunotherapy by the appropriate use of antibacterial drugs. References 1 : SWOG 8795.: A randomized comparison of bacillus Calmette-Guérin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol.1993; 149: 282A. Google Scholar 2 : Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol.1990; 143: 502. Link, Google Scholar 3 : Intravesical BCG therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of BCG. Cancer Res.1987; 47: 1762. Medline, Google Scholar 4 : Complications of bacillus Calmette-Guérin immunotherapy: A review of 2602 patients and comparison of chemotherapy complications. In: . New York: Liss1989: 335. Google Scholar 5 : Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. Urol. Res.1994; 22: 177. Crossref, Medline, Google Scholar 6 : Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J. Urol.1992; 148: 1577. Link, Google Scholar 7 : Rapid Quantitative Measurement of Drug Susceptibility of Mycobacteria. Chicago: Illinois Institute for Tuberculosis Research1973. Google Scholar 8 : Reduction of BCG fatal toxicity in mice. J. Urol.1991; 145: 858. Google Scholar 9 : L’Antibiogramme du BCG: Valeur diagnostique de la résistance a la cyclosérine. Rev. Tuberc. Pneumol. Ther.1967; 31: 1060. Medline, Google Scholar 10 : Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity. J. Urol.1992; 147: 738. Link, Google Scholar 11 DIN-Norm 58943–8: Empfindlichkeitsprüfung von Tuberkulose-bakterien gegen Chemotherapeutika. Berlin: Beuth Verlag1996. Google Scholar 12 : Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol.1981; 13: 908. Crossref, Medline, Google Scholar 13 : Anonymous examens bactériologiques en tuberculose. Paris: de la Rivière1968. Google Scholar 14 : Übersicht zur Pharmakokinetik der Antibiotika. In: . Stuttgart: Thieme Verlag1980: 710. Google Scholar 15 : Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J. Urol.1986; 135: 265. Link, Google Scholar 16 : Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res.1983; 43: 1611. Medline, Google Scholar 17 : Intravesical bacillus Calmette-Guérin-therapy for superficial bladder cancer: effect of bacillus Calmette-Guérin viability on treatment results. J. Urol.1985; 134: 48. Link, Google Scholar 18 : Augmentation of immunity to line 10 hepatoma by BCG. Comparison of different BCG preparations. Cancer1980; 46: 488. Crossref, Medline, Google Scholar 19 : Immuno-potentiation with BCG. I. Immune response to different strains and preparations. J. Natl. Cancer Inst.1973; 51: 1655. Crossref, Medline, Google Scholar 20 : Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer1993; 72: 558. Crossref, Medline, Google Scholar 21 : Bacillus Calmette-Guerin immunotherapy. Techniques and results. Urol. Clin. N. Amer.1992; 19: 557. Crossref, Medline, Google Scholar 22 : Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol.1992; 147: 596. Link, Google Scholar 23 : Metabolism of ciprofloxacin in man. In: . Leverkusch, Germany: Excerpta Medica1986. Google Scholar 24 : Complications of bacillus Calmette-Guerin immunotherapy. Urol. Clin. N. Amer.1992; 19: 565. Crossref, Medline, Google Scholar 25 : Drug therapy of bacillus Calmette-Guerin sepsis. Urol. Res.1995; 22: 373. Crossref, Medline, Google Scholar 26 : The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer. J. Urol.1991; 146: 444. Link, Google Scholar 27 : Fatal sepsis following intravesical Bacillus Calmette-Guérin administration for bladder cancer. J. Urol.1990; 144: 1328. Link, Google Scholar From the Department of Urology, Medical University of Lübeck, Lübeck and Department of Mycobacteriology, National Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Schaberg T, Brinkmann F, Feiterna-Sperling C, Geerdes-Fenge H, Hartmann P, Häcker B, Hauer B, Haas W, Heyckendorf J, Lange C, Maurer F, Nienhaus A, Otto-Knapp R, Priwitzer M, Richter E, Salzer H, Schoch O, Schönfeld N, Stahlmann R and Bauer T (2022) Tuberkulose im ErwachsenenalterPneumologie, 10.1055/a-1934-8303, VOL. 76, NO. 11, (727-819), Online publication date: 1-Nov-2022. Galsky M, Balar A, Black P, Campbell M, Dykstra G, Grivas P, Gupta S, Hoimes C, Lopez L, Meeks J, Plimack E, Rosenberg J, Shore N, Steinberg G and Kamat A (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancerJournal for ImmunoTherapy of Cancer, 10.1136/jitc-2021-002552, VOL. 9, NO. 7, (e002552), Online publication date: 1-Jul-2021. Hassen W and Motherway L (2021) Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma Chemotherapy and Immunotherapy in Urologic Oncology, 10.1007/978-3-030-52021-2_13, (159-168), . Pradere B, Schuettfort V, Mori K, Quhal F, Aydh A and Sari Motlagh R (2020) Management of de-novo urothelial carcinoma in transplanted patientsCurrent Opinion in Urology, 10.1097/MOU.0000000000000749, VOL. 30, NO. 3, (467-474), Online publication date: 1-May-2020. (2018) Immunotherapy Bladder Cancer, 10.1016/B978-0-12-809939-1.00020-5, (277-325), . Kleinclauss F, Thuret R, Murez T and Timsit M (2016) Transplantation rénale et cancers urologiquesProgrès en Urologie, 10.1016/j.purol.2016.08.009, VOL. 26, NO. 15, (1094-1113), Online publication date: 1-Nov-2016. Swietek N, Waldert M, Susani M, Schatzl G and Klatte T (2013) Intravesical bacillus Calmette-Guérin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantationDie intravesikale Instillationstherapie mit Bacillus Calmette-Guérin bei organtransplantierten Patienten mit oberflächlichem BlasenkarzinomWiener klinische Wochenschrift, 10.1007/s00508-013-0343-1, VOL. 125, NO. 7-8, (189-195), Online publication date: 1-Apr-2013. Köser C, Feuerriegel S, Summers D, Archer J and Niemann S (2012) Importance of the Genetic Diversity within the Mycobacterium tuberculosis Complex for the Development of Novel Antibiotics and Diagnostic Tests of Drug ResistanceAntimicrobial Agents and Chemotherapy, 10.1128/AAC.01641-12, VOL. 56, NO. 12, (6080-6087), Online publication date: 1-Dec-2012. Jones J and Larchian W (2012) Non–Muscle-Invasive Bladder Cancer (Ta, T1, and CIS) Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00081-5, (2335-2354.e8), . Oliveira C, Rodríguez O, Palou J and Palou-Redorta J (2011) Re: Amit R. Patel, Edmund S. Sabanegh, J. Stephen Jones, et al. Bacillus Calmette-Guérin Osteomyelitis Mimicking Spinal Metastasis from Urothelial Cell Carcinoma of the Bladder. Eur Urol 2010;58:934–7European Urology, 10.1016/j.eururo.2011.04.025, VOL. 60, NO. 1, (e7), Online publication date: 1-Jul-2011. Sexton W, Wiegand L, Correa J, Politis C, Dickinson S and Kang L (2010) Bladder Cancer: A Review of Non-Muscle Invasive DiseaseCancer Control, 10.1177/107327481001700406, VOL. 17, NO. 4, (256-268), Online publication date: 1-Oct-2010. Witjes J, Palou J, Soloway M, Lamm D, Brausi M, Spermon J, Persad R, Buckley R, Akaza H, Colombel M and Böhle A (2008) Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse EventsEuropean Urology Supplements, 10.1016/j.eursup.2008.08.001, VOL. 7, NO. 10, (667-674), Online publication date: 1-Oct-2008. Sfaxi M, Langar H, Ouni A, Riahi Y, Aidli S, Daghfous R, Abdeladhim A and Chébil M (2008) Réactions systémiques après traitement endovésical par le BCG : à propos de 4 casTherapies, 10.2515/therapie:2008009, VOL. 63, NO. 1, (43-47), Online publication date: 1-Jan-2008. Koya M, Simon M and Soloway M (2018) Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, VOL. 175, NO. 6, (2004-2010), Online publication date: 1-Jun-2006. Böhle A Der Einsatz von BCG beim oberflächlichen Harnblasenkarzinom Blasenkarzinom, 10.1007/3-540-26850-2_5, (67-72) Böhle A Therapie mit BCG beim oberflächlichen Harnblasenkarzinom Pharmakotherapie in der Urologie, 10.1007/3-540-26450-7_2, (33-41) Kassouf W and Kamat A (2014) Current state of immunotherapy for bladder cancerExpert Review of Anticancer Therapy, 10.1586/14737140.4.6.1037, VOL. 4, NO. 6, (1037-1046), Online publication date: 1-Dec-2004. DUREK C, JURCZOK A, WERNER H, JOCHAM D and B??HLE A (2002) Optimal Treatment of Systemic Bacillus Calmette-Guerin Infection:The Journal of Urology, 10.1097/00005392-200208000-00105, (826-831), Online publication date: 1-Aug-2002. Durek C, Jurczok A, Werner H, Jocham D and Böhle A (2018) Optimal Treatment of Systemic Bacillus Calmette-Guerin Infection: Investigations in an Animal ModelJournal of Urology, VOL. 168, NO. 2, (826-831), Online publication date: 1-Aug-2002. Saint F, Salomon L, Quintela R, Cicco A, Abbou C and Chopin D (2002) Classification, facteurs favorisants, prévention et traitement des effets indésirables (EI) associés au bacille de Calmette-Guérin (BCG) dans le traitement des tumeurs superficielles de vessieAnnales d'Urologie, 10.1016/S0003-4401(01)00085-7, VOL. 36, NO. 2, (120-131), . Weber G, Keller H, Durek C and Böhle A (2014) TICE BCG in der Rezidivprophylaxe und Therapie des oberflächlichen HarnblasenkarzinomsDer Urologe B, 10.1007/s001310170028, VOL. 41, NO. 5, (482-487), Online publication date: 1-Oct-2001. DUREK C, RICHTER E, BASTECK A, R??SCH-GERDES S, GERDES J, JOCHAM D and B??HLE A (2001) THE FATE OF BACILLUS CALMETTE-GUERIN AFTER INTRAVESICAL INSTILLATIONThe Journal of Urology, 10.1097/00005392-200105000-00097, (1765-1768), Online publication date: 1-May-2001. DUREK C, RICHTER E, BASTECK A, RÜSCH-GERDES S, GERDES J, JOCHAM D and BÖHLE A (2018) THE FATE OF BACILLUS CALMETTE-GUERIN AFTER INTRAVESICAL INSTILLATIONJournal of Urology, VOL. 165, NO. 5, (1765-1768), Online publication date: 1-May-2001. Lockyer C and Gillatt D (2016) BCG immunotherapy for superficial bladder cancerJournal of the Royal Society of Medicine, 10.1177/014107680109400305, VOL. 94, NO. 3, (119-123), Online publication date: 1-Mar-2001. Volume 162Issue 6December 1999Page: 1959-1962 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Keywordsbladderimmunotherapycycloserinemycobacterium bovisneoplasmsMetrics Author Information CHRISTOPH DUREK More articles by this author SABINE RÜSCH-GERDES More articles by this author DIETER JOCHAM More articles by this author ANDREAS BÖHLE More articles by this author Expand All Advertisement PDF downloadLoading ...